These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28720391)

  • 1. Recommendations for the Management of Rare Kidney Cancers.
    Giles RH; Choueiri TK; Heng DY; Albiges L; Hsieh JJ; Linehan WM; Pal S; Maskens D; Paseman B; Jonasch E; Malouf G; Molina AM; Pickering L; Shuch B; Srinivas S; Srinivasan R; Tannir NM; Bex A
    Eur Urol; 2017 Dec; 72(6):974-983. PubMed ID: 28720391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
    Ljungberg B; Albiges L; Abu-Ghanem Y; Bensalah K; Dabestani S; Fernández-Pello S; Giles RH; Hofmann F; Hora M; Kuczyk MA; Kuusk T; Lam TB; Marconi L; Merseburger AS; Powles T; Staehler M; Tahbaz R; Volpe A; Bex A
    Eur Urol; 2019 May; 75(5):799-810. PubMed ID: 30803729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
    Chen Q; Cheng L; Li Q
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of non-clear cell renal cell carcinoma: Current approaches.
    Tsimafeyeu I
    Urol Oncol; 2017 Jan; 35(1):5-13. PubMed ID: 27544302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies for non-clear renal cell carcinoma.
    Singer EA; Bratslavsky G; Linehan WM; Srinivasan R
    Target Oncol; 2010 Jun; 5(2):119-29. PubMed ID: 20680492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Metastatic Renal Cell Carcinoma with Variant Histologies.
    Flippot R; Damarla V; McGregor BA
    Urol Clin North Am; 2020 Aug; 47(3):319-327. PubMed ID: 32600534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
    Harshman LC; Choueiri TK
    Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
    Pal SK; Signorovitch JE; Li N; Zichlin ML; Liu Z; Ghate SR; Perez JR; Vogelzang NJ
    Int J Urol; 2017 Apr; 24(4):272-278. PubMed ID: 28253548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options for variant renal cancer: a true orphan disease.
    Stadler WM
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6393S-6S. PubMed ID: 15448037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current management of renal cell carcinoma.
    Kuusk T; Grivas N; de Bruijn R; Bex A
    Minerva Med; 2017 Aug; 108(4):357-369. PubMed ID: 28176516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
    Puente J; García Del Muro X; Pinto Á; Láinez N; Esteban E; Arranz JÁ; Gallardo E; Méndez MJ; Maroto P; Grande E; Suárez C
    Target Oncol; 2016 Apr; 11(2):129-41. PubMed ID: 26706236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EAU guidelines on renal cell carcinoma: 2014 update.
    Ljungberg B; Bensalah K; Canfield S; Dabestani S; Hofmann F; Hora M; Kuczyk MA; Lam T; Marconi L; Merseburger AS; Mulders P; Powles T; Staehler M; Volpe A; Bex A
    Eur Urol; 2015 May; 67(5):913-24. PubMed ID: 25616710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
    Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
    Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced treatments in non-clear renal cell carcinoma.
    Tazi el M; Essadi I; Tazi MF; Ahellal Y; M'rabti H; Errihani H
    Urol J; 2011; 8(1):1-11. PubMed ID: 21404194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Strategies for Hereditary Kidney Cancer.
    Sidana A; Srinivasan R
    Curr Oncol Rep; 2016 Aug; 18(8):50. PubMed ID: 27325049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates to the Management of Kidney Cancer.
    Jonasch E
    J Natl Compr Canc Netw; 2018 May; 16(5S):639-641. PubMed ID: 29784745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.
    Shinohara N; Abe T
    Int J Urol; 2015 Oct; 22(10):888-97. PubMed ID: 26147084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma.
    Westerman ME; Shapiro DD; Wood CG; Karam JA
    Urol Clin North Am; 2020 Aug; 47(3):329-343. PubMed ID: 32600535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.
    Malouf GG; Joseph RW; Shah AY; Tannir NM
    Clin Adv Hematol Oncol; 2017 May; 15(5):409-418. PubMed ID: 28591094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.